DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Lurtotecan
Lurtotecan
Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
WO 2017/173206 Al 5 October 2017 (05.10.2017) P O P C T
WO 2018/175958 Al 27 September 2018 (27.09.2018) W !P O PCT
Application of Ligand Based Pharmacophore Modeling and Chemical Database Mining
Doxil” and Beyond
(12) United States Patent (10) Patent No.: US 8,835,443 B2 Kawasaki Et Al
Short-Chain Ceramides for Enhancing Cytotoxicity of Liposome-Encapsulated Doxorubicin Toward Human Breast Cancer (MDA-MB-231) and Prostate Cancer (PC-3) Cells
0 Original Research Submission To: Clinical Cancer Research Title: A
Stembook 2018.Pdf
HHS Public Access Author Manuscript
Camptothecin, a Photodegradant of Lurtotecan
WO 2018/226998 Al 13 December 2018 (13.12.2018) W !P O PCT
HHS Public Access Author Manuscript
United States Patent (10) Patent No.: US 9,605,003 B2 Castro Et Al
(12) Patent Application Publication (10) Pub. No.: US 2004/0092583 A1 Shanahan-Prendergast (43) Pub
13 the Clinical Development of Lurtotecan Experience with Water-Soluble and Liposomal Forms
Providing for Duty-Free Treatment for Specified Pharmaceutical Active
Targeted Nanomedicines for Cancer Therapy, from Basics to Clinical Trials
Top View
Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
Drug Delivery Systems in Cancer Therapy
Natural Products As Lead Compounds in Drug Discovery
WO 2010/091198 Al
Pharmaceutical Compositions and Dosage Forms of Thalidomide
Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
WO 2017/091762 Al O
United States Patent $835 a 88: As: Inhibitor 1-((R)-3-(4-Amino-3-(4
Synthesis and Antitumor Activity of Pyrano[3,2-I]-Fused Camptothecin Derivatives
Molecule Anticancer Agents
Risk of Interactions with Conventional Anti-Cancer Drugs
WO 2018/144869 Al 09 August 2018 (09.08.2018) W ! P O PCT
Monomethylvaline Compounds Capable of Conjugation to Ligands
Customs Tariff - Schedule Xxi - 1
NIH Public Access Author Manuscript Nanomedicine
Gene Fragment Overexpression Screening Methodologies, and Uses Thereof
Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
Curriculum Vitae
2004 Annual Report OSI Pharmaceuticals, Inc. 2004 Annual
Phase I and Pharmacokinetic Study of Pegylated Liposomal CKD-602 in Patients with Advanced Malignancies William C
Harmonized Tariff Schedule of the United States (2006) (Rev
WO 2Ull/1563Ol A2
Nanomedicine in Non-Small Cell Lung Cancer: from Conventional Treatments to Immunotherapy
Customs Tariff - Schedule
Photobiological Properties of Photoactive Nanoparticles for the Treatment of Cancer Vadzim Reshetov
Sustainable Production of Camptothecin from an Alternaria Sp
Review Article Camptothecin (CPT) and Its Derivatives Are Known To
Amanda Alves De Oliveira
Compositions for Treating Breast Cancer
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Formula Ϊ O O W O 2011/163330 AI Llll II II 11III II I I III II II II II III II I II
Extending Time to Disease Progression Or Survival in Cancer Patients
DX-8951F), Infused Over 30 Minutes Every Three Weeks1
View U.S. Patent No. 10357539 in PDF
(12) United States Patent (10) Patent No.: US 9,561,231 B2 Hubbard Et Al
Camptothecin and Its Analogs Antitumor Activity by Poisoning
Novel Camptothecin Derivatives
Methods and Compositions Comprising a C-Terminal Bax Peptide (US)
INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri